ClinicalTrials.gg

TargetBeta

ABL1

ABL proto-oncogene 1, non-receptor tyrosine kinase · also JTK7, c-ABL, p150, ABL · SH2 domain containing

7 programs in company-led studies act on ABL1, from 5 companies: 2 in phase 3, 4 approved with new studies. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (5 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
asciminibruleNovartisphase 4167 runningBCRChEMBL
regorafenibruleBayerphase 4404 runningBRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEKChEMBL
imatinibruleNovartisphase 4703 runningBCR, KIT, PDGFRBChEMBL
nilotinibruleNovartisphase 4571 runningBCRChEMBL
olverembatinibruleAscentage Pharma Group Internationalphase 3105 runningBCR, EPHB2ChEMBL
EmbibatinibHansoh Pharmaceutical Groupphase 375 runningBCRthe company's pipeline
TQB3911Sino Biopharmaceuticalphase 111 runningBCRthe company's pipeline

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.